Skip to main content
Log in

Schwierige, therapeutisch aber relevante Abgrenzung

Typ-1-Diabetes, LADA oder „Doppeldiabetes“?

Type 1 diabetes, LADA, „double diabetes“ — differential diagnosis and therapy

  • FORTBILDUNG . SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Bei der Diagnosestellung oder Überprüfung eines schon länger bestehenden Diabetes fällt es nicht immer leicht, Patienten z. B. eindeutig als Typ-1- oder Typ-2-Diabetiker einzuordnen. Denn manche haben einen „Doppeldiabetes“. Das hat auch therapeutische Konsequenzen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2

Literatur

  1. Hawa MI & Action LADA 7 Consortium. Adult-Onset Autoimmune Diabetes in Europe is Prevalent with a broad Clinical Phenotype. Diabetes Care 2013; 36:908–913

    Article  PubMed  PubMed Central  Google Scholar 

  2. Turner R et al. Prospective Diabetes Study Group, UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes, Lancet 1997; 350:1288–1293

    Article  CAS  PubMed  Google Scholar 

  3. Tuomi T et al. The many faces of diabetes: A disease with increasing heterogeneity. Lancet 2014; 383:1084–94

    Article  PubMed  Google Scholar 

  4. Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). Eur J Endocrinol 2014; 71:697–704

    Article  Google Scholar 

  5. Krause S et al. GAD Autoantibody Affinity in Adult Patients with latent Autoimmune Diabetes, the Study Participants of a GAD65 Vaccination Trial. Diabetes Care 2014; 37:1675–1680

    Article  CAS  PubMed  Google Scholar 

  6. Williams A et al. Detection of Antibodies directed to the N-Terminal Region of GAD is dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 Diabetes. Diabetes 2015; 65:3239–3246

    Article  Google Scholar 

  7. Zhao Y, Yang L, Xiang Y, Liu L, Huang G, Long Z, Li X, Leslie RD, Wang X, Zhou Z. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 2014; 99:E876–80

    Article  CAS  PubMed  Google Scholar 

  8. Johansen OE, Boehm B, Grill V, Torjesen PA, Bhattacharya S, Patel S, Wetzel K, Woerle H-J. C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory results from a 2-year, double-blind, randomised, controlled study. Diabetes Care 2014; 37:e11–e12

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Hummel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hummel, M., Füchtenbusch, M. Typ-1-Diabetes, LADA oder „Doppeldiabetes“?. MMW - Fortschritte der Medizin 159, 52–55 (2017). https://doi.org/10.1007/s15006-017-9579-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9579-4

Keywords

Navigation